BiofronteraBFRI -3.42%44 Net Margin % is -47.12% as of Mar. 2026. GuruFocus rates BFRI with a GF Score™ of 44/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Biofrontera ranks worse than 82.85% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Biofrontera's Net Income for the
three
months ended in Mar. 2026 was $-4.75 Mil. Biofrontera's Revenue for the
three
months ended in Mar. 2026 was $10.08 Mil. Therefore, Biofrontera's net margin for the quarter that ended in Mar. 2026 was -47.12%.
The historical rank and industry rank for Biofrontera's Net Margin % or its related term are showing as below:
BFRI'
s Net Margin % Range Over the Past 10 Years
Min: -156.49 Med: -47.58 Max: -2.23
Current: -25.66
BFRI's Net Margin % is ranked worse than 82.85% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs BFRI: -25.66
Biofrontera (NAS:BFRI) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biofrontera Net Margin % Related Terms
Biofrontera Net Margin % Historical Data
* Premium members only.
The historical data trend for Biofrontera's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Net Margin % distribution charts can be found below:
* The bar in red indicates where Biofrontera's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera (BFRI) has a Net Margin % of -47.12% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Biofrontera and its competitors. According to the industry distribution chart, Biofrontera ranks #792 out of 956 companies in the Drug Manufacturers industry, placing it in the top 82.8%.
Is Biofrontera's Net Margin % too high?
Biofrontera's current Net Margin % is -47.12%. Based on the distribution chart, Biofrontera ranks #792 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofrontera has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Net Margin % compare to AKAN and CABR?
According to the Drug Manufacturers industry distribution chart, Biofrontera ranks #792 out of 956 companies for Net Margin %. This places Biofrontera in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biofrontera and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera's current Net Margin % is -47.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera (BFRI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $0.99 — trading 84.2% above its estimated fair value. The current Net Margin % is -47.12%. Biofrontera's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biofrontera (BFRI), the current Net Margin % is -47.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera (BFRI) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued.
The current stock price of $0.99 is trading 84.2% above its estimated GF Value™ of $0.54.
GuruFocus considers Biofrontera to be Significantly Overvalued.
Key valuation signals for BFRI:
Net Margin %: -47.12%
GF Value™: $0.54 vs. price of $0.99 (84.2% above fair value)
No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
44GF Score
Get the complete analysis for BFRI
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BFRI has been successfully added to your 
